Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Go back to Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy| Gilead Sciences (NASDAQ: GILD) | Delayed: 146.30 +2.58 (1.80%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.72 | 52 Week High | $108.63 | |||
| Open | $144.26 | 52 Week Low | $71.39 | |||
| Day High | $146.39 | P/E | 80.83 | |||
| Day Low | $143.71 | EPS | $1.81 | |||
| Volume | 2,638,962 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 144.54 +0.61 (0.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.93 | 52 Week High | $65.46 | |||
| Open | $146.42 | 52 Week Low | $47.97 | |||
| Day High | $147.09 | P/E | 98.33 | |||
| Day Low | $144.10 | EPS | $1.47 | |||
| Volume | 5,302,993 | |||||
